Hongbo Qi

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 101 citations

Medicine, Medicinal Chemistry, Pharmacology +17

2(<i>S</i>)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(<i>S</i>)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (<b>1</b>):  A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist

Jeffrey J. Hale, Sander G. Mills, Malcolm MacCoss et al. · Journal of Medicinal Chemistry · 1996 · 67 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +6

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Shrenik K. Shah, Shuwen He, Liangqin Guo et al. · ACS Medicinal Chemistry Letters · 2015 · 23 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

A one-pot synthesis of 3-substituted-5-carbonylmethyl-1,2,4-oxadiazoles from β-keto esters and amidoximes under solvent-free conditions

Wu Du, Quang Truong, Hongbo Qi et al. · Tetrahedron Letters · 2007 · 22 citations

Natural Sciences, Chemistry, Medicinal Chemistry +13